Focus Stocks》Pell Biomedical*-Chuang: The legal theory will be bullish, and the stock price fluctuates 19% after going up and down.

Lin Chenglong, chairman of Peer Biomedical*-Creation. (File photo)

[Reporter Chen Yongji/Report from Taipei] Peer Biomedical*-Chuang (6949) held a legal meeting yesterday and promised that the subsidiary will make a big profit jump in 2028, which drove the stock price to jump to the daily limit of 49.2 yuan today. The daily limit order once exceeded 10,000 contracts, but the limit was opened in just 5 minutes, and once it hit the limit, the stock price fluctuated up to 19%.

As of 9:57, the stock price of Peer Biomedical*-Chuang Chuang was tentatively trading at 42.9 yuan, a decrease of more than 4%, with a trading volume of 18,000 contracts.

Pair Biomedical*-Chuangyester said that the second phase clinical trial of its new anti-cancer drug PL001 (CD19 CAR-T) has been completed ahead of schedule and is expected to obtain domestic drug license in 2027. It is expected to provide localized, affordable and high-quality cell therapy options for Taiwanese lymphoma patients.

In addition, the PIC/S GMP cell manufacturing plant of Taiwan Cell Manufacturing (tcmc), a subsidiary of Peer, is located in the Hsinchu Biomedical Park. It has been officially put into operation in June this year. It has a manufacturing capacity of about 300 cases of CAR-T cell therapy per year. By introducing new equipment, it has optimized its production capacity and is moving towards 900 cases per year in 2028. Profits will make a huge leap forward. tcmc is currently planning to promote an IPO in 2027 to further strengthen the group's capital operation and expand its operating scale.